These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9692403)

  • 1. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine.
    Rego EM; Neto EB; Simões BP; Zago MA
    Am J Hematol; 1998 Aug; 58(4):340-1. PubMed ID: 9692403
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary embolism and intravenous high-dose desferrioxamine.
    Cianciulli P
    Haematologica; 1992; 77(4):368-9. PubMed ID: 1427452
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.
    Freedman MH; Grisaru D; Olivieri N; MacLusky I; Thorner PS
    Am J Dis Child; 1990 May; 144(5):565-9. PubMed ID: 2330923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 5. Desferrioxamine and urinary zinc excretion in beta-thalassemia major.
    Uysal Z; Akar N; Kemahli S; Dincer N; Arcasoy A
    Pediatr Hematol Oncol; 1993; 10(3):257-60. PubMed ID: 8217542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients.
    Hartkamp MJ; Babyn PS; Olivieri F
    Pediatr Radiol; 1993; 23(7):525-8. PubMed ID: 8309754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central venous line thrombosis in children and young adults with thalassemia major.
    Finkelstein Y; Yaniv I; Berant M; Zilber R; Garty BZ; Epstein O; Lahav J; Tamary H
    Pediatr Hematol Oncol; 2004; 21(5):375-81. PubMed ID: 15205080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
    Cianciulli P; Forte L; Sorrentino F; Palombi M; Papa G; Marciani MG
    Bone Marrow Transplant; 1993; 12 Suppl 1():5-8. PubMed ID: 8374563
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major.
    Wacker P; Halperin DS; Balmer-Ruedin D; Oberhansli I; Wyss M
    Chest; 1993 Apr; 103(4):1276-8. PubMed ID: 8131484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary syndrome and intravenous high-dose desferrioxamine.
    Castriota Scanderbeg A; Izzi GC; Butturini A; Benaglia G
    Lancet; 1990 Dec; 336(8729):1511. PubMed ID: 1979119
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
    Cianciulli P; Sorrentino F; Forte L; Palombi M; Papa G; Meloni C; Taccone Gallucci M; Casciani CU
    Haematologica; 1992; 77(6):514-5. PubMed ID: 1289188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI.
    Seif El Dien HM; Esmail RI; Magdy RE; Lotfy HM
    Pediatr Radiol; 2013 Sep; 43(9):1159-65. PubMed ID: 23563594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.
    Davis BA; Porter JB
    Blood; 2000 Feb; 95(4):1229-36. PubMed ID: 10666195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H; Goshen J; Carmi D; Yaniv I; Kaplinsky C; Cohen IJ; Zaizov R
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum superoxide dismutase levels of beta thalassemia patients and effects of high dosage of intravenous desferrioxamine treatment on superoxide dismutase levels.
    Tekin M; Akar N; Eğin Y; Cin S
    Pediatr Hematol Oncol; 1998; 15(4):371-4. PubMed ID: 9658440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.